A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): Analysis of the GIMEMA 0496 protocol

Blood

Volumn 105, Issue 9, 2005, Pages 3434-3441

  Mancini, Marco ^a   Scappaticci, Daniela ^b   Cimino, Giuseppe ^b   Nanni, Mauro ^b   Derme, Valentina ^b   Elia, Loredana ^b   Tafuri, Agostino ^b   Vignetti, Marco ^b   Vitale, Antonella ^b   Cuneo, Antonio ^b   Castoldi, Gianluigi ^b   Saglio, Giuseppe ^b   Pane, Fabrizio ^b   Mecucci, Cristina ^b   Camera, Andrea ^b   Specchia, Giorgina ^b   Tedeschi, Alessandra ^b   Di Raimondo, Francesco ^b   Fioritoni, Giuseppe ^b   Fabbiano, Francesco ^b   Marmont, Filippo ^b   Ferrara, Felicetto ^b   Cascavilla, Nicola ^b   Todeschini, Giuseppe ^b   Nobile, Francesco ^b   Kropp, Maria Grazia ^b   Leoni, Pietro ^b   Tabilio, Antonio ^b   Luppi, Mario ^b   Annino, Luciana ^b   Mandelli, Franco ^b   Foà, Robin ^b   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; E2A PBX1 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 PROTEIN; ONCOPROTEIN; PROTEIN P15; PROTEIN P16; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHROMOSOME 6Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME ISOLATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT CARE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 20944444880     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2922     Document Type: Article

References (37)

1. Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989;40:171-185.
2. Walters R, Kantarjian HM, Keating MJ, et al. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med. 1990;89:579-587.
3. The Groupe Françaìse de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlation with hematologic findings and outcome. A collaborative study of the Groupe Française de Cytogénétique Hématologique. Blood. 1996;87:3135-3142.
4. Secker-Walker LM, Prentice, HG, Durrant J, Richards S, Hall E, Harrison J, on behalf of the MRC Adult Leukemia Working Party. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA. Br J Haematol. 1997;96:601-610.
5. Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93:3983-3993.
6. Williams DL, Harris A, Williams KJ, Brosius MJ, Lemonds W. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1984;13:239-257.
7. Mitelman F. The Third International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet. 1981;4:96-98.
8. Macintyre EA, Delabesse E. Molecular approaches to the diagnosis and evaluation of lymphoid malignancies. Semin Hematol. 1999;36:373-389.
9. Third International Workshop on Chromosomes in Leukemia. Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Cancer Res. 1983;13:868-873.
10. Todeschini G, Tecchio C, Meneghini V, et al. Estimated 6-year event free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998;12:144-149.
11. Mancini M, Vegna ML, Castoldi GL, et al. Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. Leukemia. 2002;16:2055-2061.
12. Stryckmans P, Suciu S, Annino I, et al. Molecular evaluation of consolidation therapy and early allograft or autograft for BCR/ABL pos. adult acute lymphoblastic leukemia. A pilot study of EIGLE (European Intergroup of French-LALA, GIMEMA and EORTC) [abstract]. Blood. 1997;90(suppl 1):183a. Abstract 809.
13. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
14. Mitelman F. An International Systems for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
15. Gu Y, Nakamura T, Ahdler H, et al. The t(4;11) chromosome translocation of human acute leukemias involves the fusion between the ALL1 gene encoding at protein with homologies to Drosophila trithorax gene and a gene Af-4 on chromosome 4. Cell. 1992;1:701-708.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
17. Elia L, Mancini M, Moleti L, et al. A multiplex reverse transcription-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lynphoblastic leukaemia. Haematologica. 2003;388:275-279.
18. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
19. Tafuri A, Gregorj C, Petrucci MT, et al. MDR 1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974-981.
20. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
21. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
24. Faderl S, Kantarjian HM, Manshouri T, et al. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999;5:1855-1861.
25. Faderl S, Estrov Z, Kantarjian HM, et al. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a) /p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999;5:159-163.
26. Fenaux P, Lai JL, Morel P, et al. Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3. Hematol Oncol. 1989;7:307-317.
27. Heerema NA, Sather HN, Sensel MG, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:1537-1544.
28. Diccianni MB, Batova A, Yu J, et al. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leuk Res. 1997;21:549-558.
29. Nakao M, Yokota S, Kaneko H, et al. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Leukemia. 1996;10:249-254.
30. Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 1995;86:1269-1275.
31. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood. 1999;93:2380-2385.
32. Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 200;97:572-574.
33. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 1995;85:2685-2690.
34. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
35. Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87): French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood. 1994;84:1603-1612.
36. Gabert J, Vey N, Bilhou-Nabera C, et al. Improved outcome of adult patients with E2A PBX1/t(1:19) positive ALL after intensive therapy: results of the LALA-94 multicenter protocol [abstract]. Blood. 2001;98:3493a.
37. Foà R, Vitale A, Mancini M, et al. The E2A-PBX1 fusion characterises a subset of adult acute lymphoblastic leukemia with distinct biological and clinical features. Br J Haematol. 2003;120:484-487.